1-1 of 1
Keywords: Agalsidase therapy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB Study

Open Access
Subject Area:
Cardiovascular System , Nephrology
Kultigin Turkmen, Aydın Guclu, Garip Sahin, Ismail Kocyigit, Levent Demirtas, Fatih Mehmet Erdur, Erkan Sengül, Oktay Ozkan, Habib Emre, Faruk Turgut, Hilmi Unal, Murat Karaman, Cengiz Acıkel, Hasan Esen, Ebru Balli, Gulfidan Bıtırgen, Halil Zeki Tonbul, Mahmut Ilker Yılmaz, Alberto Ortiz
Journal: Kidney and Blood Pressure Research
Kidney Blood Press Res (2016) 41 (6): 1016–1024.
https://doi.org/10.1159/000452605
Published Online: 23 December 2016
..., methods, instructions or products referred to in the content or advertisements. Chronic kidney disease Fabry disease Agalsidase therapy Screening ERBP Fabry disease (OMIM # 301500) is a systemic X-linked disease characterized by the accumulation of globotriaosylceramide (GL-3) secondary...
View articletitled, The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB Study
Open the PDF for The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB Study in another window